Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer

Dr. Fidler on the Utility of Dacomitinib in EGFR-Mutant NSCLCПодробнее

Dr. Fidler on the FLAURA Trial in EGFR-Mutant NSCLCПодробнее

Osimertinib for EGFR-mutant lung cancerПодробнее

Repeat biopsy in lung cancer patients with EGFR mutationПодробнее

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancerПодробнее

Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC TreatmentПодробнее

Dr. Gold on the Future of Osimertinib in Lung CancerПодробнее

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancerПодробнее

Overview of the world of EGFR mutant lung cancersПодробнее

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancerПодробнее

Identification of EGFR Mutations Impact Overall Prognosis in Lung CancersПодробнее

Osimertinib’s Role in EGFR+ Metastatic Lung CancerПодробнее

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterationsПодробнее

Osimertinib + ipilimumab in EGFR-mutated NSCLCПодробнее

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trialПодробнее

15 Years of Advances in EGFR Mutant Lung CancerПодробнее

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLCПодробнее

Current treatment recommendations and future directions for EGFR-mutant NSCLCПодробнее

Dr. Aggarwal on Triplet Therapy in EGFR-Mutant Lung CancerПодробнее